Unknown. No published reports from anyone — patient or research-chem self-experimenter. Phase 1 trials in healthy volunteers reported headache and nausea as most common AEs but no characterization of subjective effects (this is normal for safety/PK trials — they're not designed to capture "feel"). Animal data suggesting antidepressant-like activity hints at possible mood lift, but extrapolation from forced-swim test → human subjective effect is notoriously unreliable.

What you would expect mechanistically (not validated): a Trk-PAM should produce gradual, cumulative cognitive sharpening over weeks (because it amplifies ongoing neurotrophic signaling rather than producing acute neurotransmitter release), similar in pattern to the subjective profile of cerebrolysin or semax — subtle, building, contrastively obvious only after stopping. It would not feel like modafinil or a stimulant. Onset would be gradual, with the cumulative ERK/Akt-driven plasticity changes building over the typical neurotrophic-effect window of 2–8 weeks.

The honest version: nobody knows what this feels like in a human who isn't in a controlled trial.

• Tolerance: Unknown in humans. Mechanism (amplifying endogenous BDNF/NGF) is theoretically tolerance-resistant — the system self-regulates because the drug only amplifies whatever's already happening, and BDNF's own auto-regulatory feedback should constrain runaway signaling. But no actual human or chronic-animal tolerance data exists.
• Recommended cycle: No defensible recommendation — there is no clinical experience.
• Reset protocol: N/A.

Synergistic with (theoretical, no human data)

• cerebrolysin — Cerebrolysin acts upstream by mimicking BDNF/NGF at the extracellular Trk binding site (the drug supplies the ligand). ACD-856 acts downstream by amplifying the kinase response when ligand is present. Theoretically synergistic stack: more ligand × more efficient receptor = larger downstream Akt/ERK signal. Cerebrolysin's CAPTAIN-series TBI evidence is the closest indication overlap to ACD-856's stated TBI development pathway. No human data on the combination — this is mechanism-level speculation only.
• semax / NASA (n-acetyl-semax-amidate) — Both are reported to upregulate BDNF mRNA / protein. ACD-856 would amplify whatever BDNF the semax bumps up.
• bpc-157 — BPC-157 has been reported (rodent data) to upregulate BDNF expression, particularly in injury contexts. Stack would be: BPC raises BDNF, ACD-856 makes the BDNF more effective at the receptor.
• dihexa — Dihexa's mechanism is HGF/c-Met activation → indirect BDNF release / Trk pathway involvement. Stacking dihexa + ACD-856 stacks two different upstream feeders into the same Trk-receptor downstream. Theoretically additive, but dihexa itself is research-chem only and unverified — stacking two unverified research-chems compounds the unknowns.
• af710b (Anavex 3-71) — M1 muscarinic + sigma-1 mechanism, distinct neuroprotective pathway. Theoretically complementary (different receptor systems), no overlap risk.
• TAK-653 — AMPA-receptor PAM, glutamate-side. Hits a different but parallel plasticity pathway. Complementary in theory, both are unproven in humans.

Avoid stacking with

• NGF antibody therapies (tanezumab, fasinumab) — ACD-856 amplifies the very signaling these drugs block. (Irrelevant for Dylan but flag for completeness.)
• High-dose acute TrkB agonists (7,8-DHF in superphysiological doses, dihexa at high dose) — theoretical risk of compounded over-signaling in regions with already-high BDNF tone. Mechanism makes this less concerning than for direct agonist + agonist, but caution.
• Other compounds with seizure-lowering risk — until extended human safety is in, treat ACD-856 as a possible threshold-lowerer.

Neutral / safe co-administration (theoretical, no human data)

• Modafinil, citicoline, NAC, magnesium glycinate / threonate, omega-3, curcumin, creatine, beta-alanine — no mechanistic conflict, but no human stacking data. V4 stack should be neutral.

• CYP profile: Not yet published in detail. Phase 1 PK was clean enough that no CYP interactions stood out, but no formal DDI study has been published.
• Hormonal contraceptives: Unknown.
• Other medications: Insufficient data.

• Unknown. No published pharmacogenomic data on ACD-856 metabolism. Phase 1 was n=56 + n=24 healthy adult subjects (Caucasian Swedish-trial population), insufficient to detect polymorphism effects.

Verdict on sourcing: Effectively not available through any vendor Dylan would use. Everychem is on his AVOID list; Probechem has no community track record. There is no Indian-pharmacy / Russian-vendor / well-reviewed US research-chem path to verified material. This is a sourcing-blocked compound, independent of medical fit.

If/when this compound becomes usable:

• Baseline (before starting):
  • Serum BDNF (peripheral, weak proxy — rises chronically with neurotrophic interventions)
  • NfL (neurofilament light) — concussion / neurodegeneration biomarker
  • GFAP, S100B — astrocyte injury markers (relevant for athletes)
  • hsCRP, IL-6 — inflammation
  • Cognitive baseline (CNS Vital Signs / Cambridge Brain Sciences / Cogstate)
  • Lipase + amylase — Phase 1 MAD signal in 2/24 subjects, monitor pancreatic enzymes
  • LFTs, CBC
• During use:
  • Lipase + amylase q4–8 weeks
  • LFTs q8 weeks
  • Cognitive panel q12 weeks (look for week-by-week deltas, not single-session noise)
  • qEEG theta/beta ratio — if accessible — direct target-engagement biomarker per Phase 1 MAD data
• Post-cycle (if cycled): Cognitive panel + serum BDNF to test for residual / persistent effects (mechanism predicts some persistence).